Identifying key immunological and molecular pathways that drive disease exacerbation in atopic dermatitis

Withdrawn

• Conditions: atopic eczema; eczema; 10014982

• Registration Number: NL-OMON42484
• Lead Sponsor: MedImmune Biotech

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 90

Inclusion Criteria

* adults (*18 years of age);and for:
* group a (n<=30): diagnosis of AD (according to the criteria of Hanifin and Raijka) with a SASSAD score over 15 at time of inclusion, with an uncontrolled AD using a maintenance dose of local topical steroids as mentioned in the outpatient clinic protocol. These patients need oral immunosuppressive drugs to control their AD
*group b(n<=30): diagnosis of AD (according to the criteria of Hanifin and Raijka) with a SASSAD score over 15 at time of inclusion, with a controlled AD using a maintenance dose of local topical steroids as mentioned in the outpatient clinic protocol
*group c(n<=15): diagnosis of AD (according to the criteria of Hanifin and Raijka) with a SASSAD score <15 at time of inclusion
*group d (n<=15): healthy participants without a history of AD, allergic rhinitis or asthma.

Exclusion Criteria

* on systemic therapy at time of recruitment
* previous receipt of any investigational agent within 4 weeks prior to recruitment or within 5 half-lives of the investigational agent, whichever is longer
*evidence of other skin conditions, including, but not limited to, T-cell lymphoma or allergic contact dermatitis
*not willing to be biopsied;group d: a history of AD, allergic rhinitis or asthma.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified